FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
13 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.
Sponsor: Fate Therapeutics
You may qualify if…
- ✓ Histopathological or cytologically confirmed locally advanced or metastatic cancer that meets protocol-defined criteria
- ✓ Disease that is not amenable to curative therapy, with prior therapies defined by specific tumor types
- ✓ Contraceptive use by women and men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- ✓ Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- ✓ Presence of measurable disease by RECIST, v1.1 assessed within 28 days prior to start of first study intervention
- ✓ Anticipated life expectancy of at least 3 months
You may not qualify if…
- ✕ Females who are pregnant or breastfeeding
- ✕ Evidence of inadequate organ function
- ✕ Clinically significant cardiovascular disease
- ✕ Known active central nervous system (CNS) involvement by malignancy
- ✕ Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions within 2 years prior to study enrollment
- ✕ Active bacterial, fungal, or viral infections
- ✕ Prior receipt of chimeric antigen receptor (CAR) T-cell therapy, other cellular therapy, or a FATE investigational human induced pluripotent stem cell (iPSC) product
- ✕ History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out based on imaging at screening
Where it's recruiting
Gilbert
La Jolla
New Haven
Chicago
Detroit
Minneapolis
St Louis
New York
Cincinnati · Columbus
Oklahoma City
Philadelphia
Nashville
Source: ClinicalTrials.gov · NCT06241456 · last updated 2025-12-09